Skip to Main Content

Paper Details

Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
J Natl Cancer Inst
4
2023
Author NameAffiliation
Roy S HerbstYale Cancer Center
  • 1 - 1

Datasets

Release 1.2